RSC Advances,
Journal Year:
2025,
Volume and Issue:
15(5), P. 3570 - 3591
Published: Jan. 1, 2025
New
benzothiazole-1,2,3-triazole
hybrids-based
hydrazone/thiosemicarbazone
derivatives
exhibited
potent
EGFR
inhibitors
with
cytotoxicity
against
breast
cancer.
Expert Opinion on Drug Discovery,
Journal Year:
2024,
Volume and Issue:
19(4), P. 451 - 470
Published: March 8, 2024
Introduction
The
current
drug
discovery
paradigm
of
'one
drug,
multiple
targets'
has
gained
attention
from
both
the
academic
medicinal
chemistry
community
and
pharmaceutical
industry.
This
is
in
response
to
urgent
need
for
effective
agents
treat
multifactorial
chronic
diseases.
molecular
hybridization
strategy
a
useful
tool
that
been
widely
explored,
particularly
last
two
decades,
design
multi-target
drugs.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: Nov. 26, 2024
Epigenetics
governs
a
chromatin
state
regulatory
system
through
five
key
mechanisms:
DNA
modification,
histone
RNA
remodeling,
and
non-coding
regulation.
These
mechanisms
their
associated
enzymes
convey
genetic
information
independently
of
base
sequences,
playing
essential
roles
in
organismal
development
homeostasis.
Conversely,
disruptions
epigenetic
landscapes
critically
influence
the
pathogenesis
various
human
diseases.
This
understanding
has
laid
robust
theoretical
groundwork
for
developing
drugs
that
target
epigenetics-modifying
pathological
conditions.
Over
past
two
decades,
growing
array
small
molecule
targeting
such
as
methyltransferase,
deacetylase,
isocitrate
dehydrogenase,
enhancer
zeste
homolog
2,
have
been
thoroughly
investigated
implemented
therapeutic
options,
particularly
oncology.
Additionally,
numerous
epigenetics-targeted
are
undergoing
clinical
trials,
offering
promising
prospects
benefits.
review
delineates
epigenetics
physiological
contexts
underscores
pioneering
studies
on
discovery
implementation
drugs.
include
inhibitors,
agonists,
degraders,
multitarget
agents,
aiming
to
identify
practical
challenges
avenues
future
research.
Ultimately,
this
aims
deepen
epigenetics-oriented
strategies
further
application
settings.
Cellular and Molecular Immunology,
Journal Year:
2024,
Volume and Issue:
21(12), P. 1376 - 1409
Published: Nov. 8, 2024
АBSTRACT:
With
increasing
incidence
and
geography,
cancer
is
one
of
the
leading
causes
death,
reduced
quality
life
disability
worldwide.
Principal
progress
in
development
new
anticancer
therapies,
improving
efficiency
immunotherapeutic
tools,
personification
conventional
therapies
needs
to
consider
cancer-specific
patient-specific
programming
innate
immunity.
Intratumoral
TAMs
their
precursors,
resident
macrophages
monocytes,
are
principal
regulators
tumor
progression
therapy
resistance.
Our
review
summarizes
accumulated
evidence
for
subpopulations
number
biomarkers,
indicating
predictive
value
clinical
parameters
carcinogenesis
resistance,
with
a
focus
on
solid
cancers
non-infectious
etiology.
We
present
state-of-the-art
knowledge
about
tumor-supporting
functions
at
all
stages
highlight
recently
identified
by
single-cell
spatial
analytical
methods,
that
discriminate
between
tumor-promoting
tumor-inhibiting
TAMs,
where
both
subtypes
express
combination
prototype
M1
M2
genes.
focuses
novel
mechanisms
involved
crosstalk
among
epigenetic,
signaling,
transcriptional
metabolic
pathways
TAMs.
Particular
attention
has
been
given
link
cell
metabolism
epigenetic
histone
lactylation,
which
can
be
responsible
unlimited
protumoral
Finally,
we
explain
how
interfere
currently
used
therapeutics
summarize
most
advanced
data
from
trials,
divide
into
four
categories:
inhibition
TAM
survival
differentiation,
monocyte/TAM
recruitment
tumors,
functional
reprogramming
genetic
enhancement
macrophages.
Journal of Hematology & Oncology,
Journal Year:
2024,
Volume and Issue:
17(1)
Published: Oct. 10, 2024
Pancreatic
cancer
remains
one
of
the
most
aggressive
solid
tumors.
As
a
systemic
disease,
despite
improvement
multi-modality
treatment
strategies,
prognosis
pancreatic
was
not
improved
dramatically.
For
resectable
or
borderline
patients,
surgical
strategy
centered
on
improving
R0
resection
rate
is
consensus;
however,
role
neoadjuvant
therapy
in
patients
and
optimal
chemotherapy
with
without
radiotherapy
were
debated.
Postoperative
adjuvant
gemcitabine/capecitabine
mFOLFIRINOX
recommended
regardless
margin
status.
Chemotherapy
as
first-line
for
advanced
metastatic
included
FOLFIRINOX,
gemcitabine/nab-paclitaxel,
NALIRIFOX
regimens
whereas
5-FU
plus
liposomal
irinotecan
only
standard
care
second-line
therapy.
Immunotherapy
an
innovative
although
anti-PD-1
antibody
currently
agent
approved
by
MSI-H,
dMMR,
TMB-high
tumors,
which
represent
very
small
subset
cancers.
Combination
strategies
to
increase
immunogenicity
overcome
immunosuppressive
tumor
microenvironment
may
sensitize
immunotherapy.
Targeted
therapies
represented
PARP
KRAS
inhibitors
are
also
under
investigation,
showing
benefits
progression-free
survival
objective
response
rate.
This
review
discusses
current
modalities
highlights
cancer.
Pharmacological Research,
Journal Year:
2024,
Volume and Issue:
204, P. 107205 - 107205
Published: May 6, 2024
Triple-negative
breast
cancer
(TNBC)
is
an
aggressive
subtype
lacking
estrogen
receptors,
progesterone
receptors
and
lacks
HER2
overexpression.
This
absence
of
critical
molecular
targets
poses
significant
challenges
for
conventional
therapies.
Immunotherapy,
remarkably
immune
checkpoint
blockade,
offers
promise
TNBC
treatment,
but
its
efficacy
remains
limited.
Epigenetic
dysregulation,
including
altered
DNA
methylation,
histone
modifications,
imbalances
in
regulators
such
as
BET
proteins,
plays
a
crucial
role
development
resistance
to
treatment.
Hypermethylation
tumor
suppressor
gene
promoters
the
imbalance
methyltransferases
EZH2
deacetylases
(HDACs)
profoundly
influence
cell
proliferation,
survival,
metastasis.
In
addition,
epigenetic
alterations
critically
shape
microenvironment
(TME),
composition,
cytokine
signaling,
expression,
ultimately
contributing
evasion.
Targeting
these
mechanisms
with
specific
inhibitors
HDAC
combination
immunotherapy
represents
compelling
strategy
remodel
TME,
potentially
overcoming
evasion
enhancing
therapeutic
outcomes
TNBC.
review
aims
comprehensively
elucidate
current
understanding
modulation
TNBC,
on
potential
combining
therapies
overcome
posed
by
this
subtype.
Cells,
Journal Year:
2025,
Volume and Issue:
14(7), P. 538 - 538
Published: April 3, 2025
Stem
cells
have
emerged
as
a
pivotal
area
of
research
in
the
field
oncology,
offering
new
insights
into
mechanisms
cancer
initiation,
progression,
and
resistance
to
therapy.
This
review
provides
comprehensive
overview
role
stem
cancer,
focusing
on
(CSCs),
their
characteristics,
implications
for
We
discuss
origin
identification
CSCs,
tumorigenesis,
metastasis,
drug
resistance,
potential
therapeutic
strategies
targeting
CSCs.
Additionally,
we
explore
use
normal
therapy,
tissue
regeneration
delivery
vehicles
anticancer
agents.
Finally,
highlight
challenges
future
directions
cell
cancer.
